Healthcare
Xeno Transplants Corporation(XENO)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 18, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- +61.0%
- Dividend Yield
- 0.0%
Coverage: 253 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xeno Transplants Corporation (XENO) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +61.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +61.0%, free cash flow -1909.5% with operating margin 0.0% and ROIC 33.2%. Stock Foundry combines XENO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +61.0%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XENO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XENO Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for XENO and SPY.
Company Overview
Xeno Transplants Corporation
Other OTC
Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine. Xeno Transplants Corporation was incorporated in 2004 and is based in Brookline, Massachusetts.
- Leadership
- Elliot Lebowitz
- IPO Date
- Aug 1, 2006
- Street Address
- 143 Gardner Road
- Mailing
- Brookline, MA, 02445
- Region
- Brookline, MA, US
- Reporting Currency
- USD
- Investor Line
- 617-566-5228
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.2
- Price/Sales
- —
- Price/Book
- 0.0
Growth
- Revenue
- 0.0%
- EPS
- +61.0%
- Free Cash Flow
- -1909.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -68.6%
- ROIC
- 33.2%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.